Tumores Gastrintestinais
Estudo randomizado | Sintilimabe com bevacizumabe biossimilar vs. sorafenibe no carcinoma hepatocelular irressecável.
22 Jul, 2021 | 12:59hSintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
In a phase III trial involving 571 pts with unresectable HCC, the anti-PD-1 mAb sintilimab + the bevacizumab biosimilar IBI305 improved PFS (median 4.6 vs 2.8 months with sorafenib; HR 0.56, P <0.0001) & OS (median NR vs 10.4 months; HR 0.57, P <0.0001), https://t.co/UF43FGdMMy
— NatureRevClinOncol (@NatRevClinOncol) June 22, 2021
Atualização da Diretriz de Prática Clínica da AGA para quimioprevenção do câncer colorretal.
16 Jul, 2021 | 09:47h
Comentário no Twitter
Out now in @AGA_CGH: AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia. Had great time working on this with @AasmaShaukatMD & @seth_crockett. Hope it's a useful reference! @AmerGastroAssn
https://t.co/UB5hFMq6hc pic.twitter.com/KwHeKjU2dk— Peter Liang, MD MPH (@petersliang) February 19, 2021
Impacto global do câncer atribuído ao consumo de álcool – “Em termos globais, estima-se que 741.300 casos, ou 4,1% de todos os novos casos de câncer em 2020, foram atribuídos ao consumo de álcool.”
14 Jul, 2021 | 11:36hComunicado de imprensa: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet
Comentários: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian E Expert reaction to study of alcohol and cancer – Science Media Centre
Estudo randomizado | Eficácia de longo prazo da quimiorradioterapia neoadjuvante somada à cirurgia para o tratamento de carcinoma esofágico de células escamosas localmente avançado.
13 Jul, 2021 | 11:09h
Comentário no Twitter
Long-term outcomes from the NEOCRTEC5010 demonstrated the survival benefit of neoadjuvant chemoradiotherapy followed by surgery compared with surgery alone for patients with locally advanced esophageal squamous cell carcinoma https://t.co/UBBEEAynsy
— JAMA Surgery (@JAMASurgery) June 29, 2021
Câncer anal: Diretrizes de Prática Clínica da ESMO para diagnóstico, tratamento e seguimento.
1 Jul, 2021 | 10:10h
Comentário no Twitter
Now available in Annals of Oncology, the @myESMO clinical practice guidelines for the diagnosis, treatment and follow-up of anal cancer, a rare disease accounting for less than 1% of all cancers https://t.co/usnFsd00BJ pic.twitter.com/bI0v60j8Ft
— Annals of Oncology (@Annals_Oncology) June 30, 2021
Diretrizes de prática clínica baseada em evidências para tratamento de pólipos colorretais.
25 Jun, 2021 | 10:31hEstudo randomizado: Quimioterapia de intensidade reduzida em pacientes idosos frágeis com câncer gastresofágico avançado propicia uma melhor experiência ao paciente, sem perda significativa no controle da doença.
20 Mai, 2021 | 10:42h
Comentário no Twitter
The GO2 trial tested reduced intensity of chemo for pts w adv gastroesophageal cancer & found reducing intensity led to comparable survival but w improved patient experience, & decision-making can be enhanced using geriatric assessment https://t.co/DtZOXcozo7 #GeriOnc
— JAMA Oncology (@JAMAOnc) May 13, 2021
Resultados de longo prazo em estudo randomizado confirmam os benefícios da quimiorradioterapia neoadjuvante somada à cirurgia para câncer esofágico.
20 Mai, 2021 | 10:41h
Comentários no Twitter
Out at @ASCO_pubs
🔟yr Outcome of Neoadj #Chemoradiotherapy➕Surgery for #EsophagealCancer☑️Show OS benefit in locally advanced resectable esophageal or junctional #Cancer who receive preop chemorad🧪☢️ According to CROSS, persists at least🔟years‼️https://t.co/yJSibSveAh pic.twitter.com/UssnzuFiEe
— Gil Morgan (@weoncologists) May 14, 2021
Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists – 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck pic.twitter.com/2JwV0iOvoB
— ASCO Publications (@ASCO_pubs) May 5, 2021
Diretriz USPSTF: Iniciar o rastreamento para câncer colorretal aos 45 anos para a maioria dos pacientes.
19 Mai, 2021 | 09:39hScreening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
Relatório de evidências: Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editoriais: US Preventive Services Task Force Recommendations for Colorectal Cancer Screening: Forty-Five Is the New Fifty – JAMA E Updated USPSTF Guidelines for Colorectal Cancer Screening: The Earlier the Better – JAMA Surgery E Colorectal Cancer Screening Starting at Age 45 Years—Ensuring Benefits Are Realized by All – JAMA Network Open
Entrevista com o autor: USPSTF Recommendation: Screening for Colorectal Cancer
Página do paciente JAMA: Screening for Colorectal Cancer
Guia para potencializar a recuperação de pacientes oncológicos submetidos a cirurgia: ERAS para pacientes de cirurgia citorredutora com ou sem quimioterapia hipertérmica intraperitoneal.
19 Mai, 2021 | 09:24hDiretrizes relacionadas:
Ver também: Enhanced Recovery After Surgery (ERAS) Society Guidelines